MDACC Study No:RTOG1102 ( NCT No: NCT01298401)
Title:A Phase I Study of Induction Ganitumab (IND #113278) and Gemcitabine, followed by Ganitumab, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) with Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer
Principal Investigator:Christopher H. Crane
Treatment Agent:Capecitabine; GANITUMAB; Gemcitabine; Radiation
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of ganitumab that can be combined with standard chemotherapy (gemcitabine and
capecitabine) and radiation for patients with locally-advanced pancreatic
cancer. The safety of this combination will also be studied.

Ganitumab is a protein that can attach to a very specific part of a cell, which
may cause cancer cells to die.

Gemcitabine is designed to block the growth of cancer cells, which may cause
cancer cells to die.

Capecitabine is designed to interfere with the growth of cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Pancreas
Phase of Study:Phase I
Treatment Agents:Capecitabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:RTOG
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Christopher H. Crane
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults